{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:13:14Z","timestamp":1788235994850,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the 2024 Shantou Municipal Healthcare Science and Technology Plan","award":["240423126497225"],"award-info":[{"award-number":["240423126497225"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-026-02729-x","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:56:29Z","timestamp":1782111389000},"page":"1515-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Super learner model for predicting carotid plaque regression in type 2 diabetes on PCSK9 inhibitors"],"prefix":"10.1007","volume":"63","author":[{"given":"Jingyao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-5865","authenticated-orcid":false,"given":"Jia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2729_CR1","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1038\/s41598-019-42700-1","volume":"9","author":"Y-R Cho","year":"2019","unstructured":"Cho Y-R, Ann SH, Won K-B et al (2019) Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep 9:6129. https:\/\/doi.org\/10.1038\/s41598-019-42700-1","journal-title":"Sci Rep"},{"key":"2729_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12933-019-0893-2","volume":"18","author":"A da Silva","year":"2019","unstructured":"da Silva A, Caldas APS, Hermsdorff HHM et al (2019) Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovasc Diabetol 18:89. https:\/\/doi.org\/10.1186\/s12933-019-0893-2","journal-title":"Cardiovasc Diabetol"},{"key":"2729_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.47391\/JPMA.22-63","volume":"72","author":"VK Ramdas Nayak","year":"2022","unstructured":"Ramdas Nayak VK, Satheesh P, Shenoy MT, Kalra S (2022) Triglyceride Glucose (TyG) Index: A surrogate biomarker of insulin resistance. JPMA J Pak Med Assoc 72:986\u2013988. https:\/\/doi.org\/10.47391\/JPMA.22-63","journal-title":"JPMA J Pak Med Assoc"},{"key":"2729_CR4","doi-asserted-by":"publisher","unstructured":"Ms S, Rp G, Ac K et al (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376. https:\/\/doi.org\/10.1056\/NEJMoa1615664","DOI":"10.1056\/NEJMoa1615664"},{"key":"2729_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 379:2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"2729_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499. https:\/\/doi.org\/10.1056\/NEJMoa1501031","journal-title":"N Engl J Med"},{"key":"2729_CR7","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2016) Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 316:2373\u20132384. https:\/\/doi.org\/10.1001\/jama.2016.16951","journal-title":"JAMA"},{"key":"2729_CR8","doi-asserted-by":"publisher","first-page":"e19371","DOI":"10.1016\/j.heliyon.2023.e19371","volume":"9","author":"F Lu","year":"2023","unstructured":"Lu F, Li E, Yang X (2023) The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9. Heliyon 9:e19371. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19371","journal-title":"Heliyon"},{"key":"2729_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12944-025-02488-8","volume":"24","author":"X Duan","year":"2025","unstructured":"Duan X, Zhang M, Sun X et al (2025) A LASSO-derived model for the prediction of nonattainment of target LDL-C reduction with PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease. Lipids Health Dis 24:65. https:\/\/doi.org\/10.1186\/s12944-025-02488-8","journal-title":"Lipids Health Dis"},{"key":"2729_CR10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.clinthera.2022.08.005","volume":"44","author":"S Iqbal","year":"2022","unstructured":"Iqbal S, Sabbour HM, Siddiqui MS et al (2022) The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population. Clin Ther 44:1297\u20131309. https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.005","journal-title":"Clin Ther"},{"key":"2729_CR11","doi-asserted-by":"publisher","first-page":"1390352","DOI":"10.3389\/fendo.2024.1390352","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Tang C, Wang S et al (2024) A stacking ensemble model for predicting the occurrence of carotid atherosclerosis. Front Endocrinol 15:1390352. https:\/\/doi.org\/10.3389\/fendo.2024.1390352","journal-title":"Front Endocrinol"},{"key":"2729_CR12","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1093\/cvr\/cvad106","volume":"119","author":"QS Chen","year":"2023","unstructured":"Chen QS, Bergman O, Ziegler L et al (2023) A machine learning based approach to identify carotid subclinical atherosclerosis endotypes. Cardiovasc Res 119:2594\u20132606. https:\/\/doi.org\/10.1093\/cvr\/cvad106","journal-title":"Cardiovasc Res"},{"key":"2729_CR13","doi-asserted-by":"publisher","first-page":"e1001146","DOI":"10.1371\/journal.pgen.1001146","volume":"6","author":"S Okser","year":"2010","unstructured":"Okser S, Lehtim\u00e4ki T, Elo LL et al (2010) Genetic variants and their interactions in the prediction of increased pre-clinical carotid atherosclerosis: the cardiovascular risk in young Finns study. PLoS Genet 6:e1001146. https:\/\/doi.org\/10.1371\/journal.pgen.1001146","journal-title":"PLoS Genet"},{"key":"2729_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000343145","volume":"34","author":"P-J Touboul","year":"2012","unstructured":"Touboul P-J, Hennerici MG, Meairs S et al (2012) Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis Basel Switz 34:290\u2013296. https:\/\/doi.org\/10.1159\/000343145","journal-title":"Cerebrovasc Dis Basel Switz"},{"key":"2729_CR15","doi-asserted-by":"publisher","first-page":"20440","DOI":"10.1038\/s41598-024-71454-8","volume":"14","author":"T-C Li","year":"2024","unstructured":"Li T-C, Lin C-C, Liu C-S et al (2024) Heritability of carotid intima-media thickness and inflammatory factors of atherosclerosis in a Chinese population. Sci Rep 14:20440. https:\/\/doi.org\/10.1038\/s41598-024-71454-8","journal-title":"Sci Rep"},{"key":"2729_CR16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.5551\/jat.43141","volume":"25","author":"N Katakami","year":"2018","unstructured":"Katakami N, Mita T, Gosho M et al (2018) Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies. J Atheroscler Thromb 25:1053\u20131066. https:\/\/doi.org\/10.5551\/jat.43141","journal-title":"J Atheroscler Thromb"},{"key":"2729_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/CIRCULATIONAHA.106.645606","volume":"116","author":"JJ Cao","year":"2007","unstructured":"Cao JJ, Arnold AM, Manolio TA et al (2007) Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 116:32\u201338. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.645606","journal-title":"Circulation"},{"key":"2729_CR18","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459\u20132472. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"2729_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/lipd.12432","volume":"60","author":"AZ Luu","year":"2025","unstructured":"Luu AZ, Hajiesmaeili Y, Faezi S et al (2025) Regression of carotid atherosclerosis in high-risk individuals with proprotein convertase subtilisin\/kexin type 9 inhibitors. Lipids 60:165\u2013169. https:\/\/doi.org\/10.1002\/lipd.12432","journal-title":"Lipids"},{"key":"2729_CR20","doi-asserted-by":"publisher","first-page":"E835","DOI":"10.1002\/ccd.29231","volume":"97","author":"TC Aranzulla","year":"2021","unstructured":"Aranzulla TC, Musumeci G (2021) Morphological stabilization and regression of carotid plaque following therapy with evolocumab in a high-risk patient. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 97:E835\u2013E841. https:\/\/doi.org\/10.1002\/ccd.29231","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"key":"2729_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00701-019-03825-4","volume":"161","author":"A Ogata","year":"2019","unstructured":"Ogata A, Oho K, Matsumoto N et al (2019) Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien) 161:597\u2013600. https:\/\/doi.org\/10.1007\/s00701-019-03825-4","journal-title":"Acta Neurochir (Wien)"},{"key":"2729_CR22","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.1002\/ccd.29743","volume":"98","author":"TC Aranzulla","year":"2021","unstructured":"Aranzulla TC, Piazza S, Ricotti A et al (2021) CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 98:E115\u2013E121. https:\/\/doi.org\/10.1002\/ccd.29743","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"key":"2729_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/CIRCRESAHA.118.313911","volume":"124","author":"AJ Sweatt","year":"2019","unstructured":"Sweatt AJ, Hedlin HK, Balasubramanian V et al (2019) Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circ Res 124:904\u2013919. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313911","journal-title":"Circ Res"},{"key":"2729_CR24","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1093\/eurheartj\/ehy712","volume":"39","author":"J Tromp","year":"2018","unstructured":"Tromp J, Ouwerkerk W, Demissei BG et al (2018) Novel endotypes in heart failure: effects on guideline-directed medical therapy. Eur Heart J 39:4269\u20134276. https:\/\/doi.org\/10.1093\/eurheartj\/ehy712","journal-title":"Eur Heart J"},{"key":"2729_CR25","doi-asserted-by":"publisher","first-page":"103776","DOI":"10.1016\/j.ebiom.2021.103776","volume":"75","author":"A Baghela","year":"2022","unstructured":"Baghela A, Pena OM, Lee AH et al (2022) Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures. EBioMedicine 75:103776. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103776","journal-title":"EBioMedicine"},{"key":"2729_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE et al (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Lond Engl 400:997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4","journal-title":"Lancet Lond Engl"},{"key":"2729_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.119.044434","volume":"141","author":"A Damask","year":"2020","unstructured":"Damask A, Steg PG, Schwartz GG et al (2020) Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation 141:624\u2013636. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044434","journal-title":"Circulation"},{"key":"2729_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2478\/jtim-2024-0014","volume":"12","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Yu B, Chao C et al (2024) Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition). J Transl Intern Med 12:325\u2013343. https:\/\/doi.org\/10.2478\/jtim-2024-0014","journal-title":"J Transl Intern Med"},{"key":"2729_CR29","doi-asserted-by":"publisher","unstructured":"Ne YH L (2018) PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc 7. https:\/\/doi.org\/10.1161\/JAHA.118.008953","DOI":"10.1161\/JAHA.118.008953"},{"key":"2729_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s J-P et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154\u2013156. https:\/\/doi.org\/10.1038\/ng1161","journal-title":"Nat Genet"},{"key":"2729_CR31","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S et al (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283:2363\u20132372. https:\/\/doi.org\/10.1074\/jbc.M708098200","journal-title":"J Biol Chem"},{"key":"2729_CR32","doi-asserted-by":"publisher","unstructured":"C C, S DT, R R, et al (2019) Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol 18. https:\/\/doi.org\/10.1186\/s12933-019-0949-3","DOI":"10.1186\/s12933-019-0949-3"},{"key":"2729_CR33","doi-asserted-by":"publisher","first-page":"639727","DOI":"10.3389\/fcvm.2021.639727","volume":"8","author":"A Luquero","year":"2021","unstructured":"Luquero A, Badimon L, Borrell-Pages M (2021) PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation. Front Cardiovasc Med 8:639727. https:\/\/doi.org\/10.3389\/fcvm.2021.639727","journal-title":"Front Cardiovasc Med"},{"key":"2729_CR34","unstructured":"Abstract 19753 (2025) Hdl Cholesterol Efflux Capacity is Inversely Associated With Incident Chd Events Independent of Hdl-c and Apoa-i Concentrations | Circulation. https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/circ.130.suppl_2.19753. Accessed 11 Oct"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02729-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:15:03Z","timestamp":1788232503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02729-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02729-x","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of ZhuJiang Hospital of Southern Medical University (2025-KY-189-01, approved on June 25, 2025) and the Medical Ethics Committee of the Second Affiliated Hospital of Shantou University Medical College (2025-20, approved on February 13, 2025). The requirement for informed consent was waived due to the retrospective nature of the study, and all analyses were performed using anonymized clinical data.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors gave their consent to publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}